Released : November 14, 2018 07:00 RNS Number : 2611H MaxCyte, Inc. 14 November 2018 MaxCyte, Inc. ("MaxCyte") Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement Precision BioSciences gains rights to MaxCyte's cell engineering technology to develop
Released : November 12, 2018 07:00 RNS Number : 9788G MaxCyte, Inc. 12 November 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Announces Research Agreement with Kite, a Gilead Company Gaithersburg, Maryland - 12 November 2018: MaxCyte (LSE: MXCT, MXCR), the global
Released : November 09, 2018 07:00 RNS Number : 8499G MaxCyte, Inc. 09 November 2018 MaxCyte, Inc. ("MaxCyte") CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement
Released : October 31, 2018 16:25 RNS Number : 9281F MaxCyte, Inc. 31 October 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Result of AGM Gaithersburg, MD - 31 October 2018 : MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, announces that at its
Released : October 10, 2018 07:00 RNS Number : 4884D MaxCyte, Inc. 10 October 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Commences Dosing in First Clinical Trial in Solid Tumours First patient dosed in Phase I clinical study to evaluate MaxCyte's lead CAR therapeutic in
Released : October 08, 2018 07:00 RNS Number : 2057D MaxCyte, Inc. 08 October 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Notification of Annual General Meeting Gaithersburg, MD - 08 October 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company
Released : September 24, 2018 07:00 RNS Number : 6299B MaxCyte, Inc. 24 September 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Results for the Six Months ended 30 June 2018 Gaithersburg, Maryland - 24 September 2018 - MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and
Released : September 10, 2018 07:00 RNS Number : 2308A MaxCyte, Inc. 10 September 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Maryland, USA - 10 September 2018: MaxCyte (LSE: MXCT, MXCR), a US-based global company dedicated to driving the acceleration of the
Released : September 03, 2018 07:00 RNS Number : 4933Z MaxCyte, Inc. 03 September 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Half Year Results Gaithersburg, MD - 03 September 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company , will
Released : July 26, 2018 17:33 RNS Number : 9375V MaxCyte, Inc. 26 July 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Person Closely Associated Dealing Maryland, USA , 26 July 2018 - MaxCyte (LSE: MXCT, MXCR) the global cell-based medicines and technology company, announces that
